Showing 211-220 of 9661 results for "".
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap
- Randomized Trial Evaluates Educational Delivery Methods for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/randomized-trial-evaluates-educational-delivery-methods-for-pediatric-atopic-dermatitis/2487170/A randomized controlled trial published online in Pediatric Dermatology found that video-based therapeutic patient education (TPE) did not significantly outperform standard educational handouts for pediatric atopic dermatiti
- Systematic Review Highlights Comparative Outcomes Across Molluscum Contagiosum Therapieshttps://practicaldermatology.com/news/systematic-review-highlights-comparative-outcomes-across-molluscum-contagiosum-therapies/2487169/A new systematic review evaluating treatments for molluscum contagiosum (MC) found that curettage, potassium hydroxide (KOH), autoinoculation, and podophyllotoxin demonstrated some of the highest lesion clearance rates among currently available therapies, while ne
- Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height: Analysishttps://practicaldermatology.com/news/isotretinoin-use-in-adolescence-not-linked-to-reduced-adult-height-analysis/2487168/Concerns that isotretinoin therapy during adolescence could impair skeletal growth were not supported by findings from a large nationwide Danish study published in
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://practicaldermatology.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- Combination Ixekizumab and Tirzepatide Therapy Outperforms Ixekizumab Alone in Psoriasishttps://practicaldermatology.com/news/combination-ixekizumab-and-tirzepatide-therapy-outperforms-ixekizumab-alone-in-psoriasis/2487115/Concomitant treatment with ixekizumab (Taltz, Eli Lilly and Company) and tirzepatide (Zepbound, Eli Lilly and Company) led to superior skin clearance and quality-of-life outcomes compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and
- Measure Up Data Support Long-Term Laboratory Safety With Upadacitinib in Atopic Dermatitishttps://practicaldermatology.com/news/measure-up-data-support-long-term-laboratory-safety-with-upadacitinib-in-atopic-dermatitis/2487114/Most laboratory parameters remained within normal limits through 140 weeks of upadacitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to findings presented at the 2026 Society for Investigative Dermatology Annual
- Meta-Analysis: HS Linked with Elevated Cardiovascular Riskhttps://practicaldermatology.com/news/meta-analysis-hs-linked-with-elevated-cardiovascular-risk/2487046/Patients with hidradenitis suppurativa (HS) may face an increased burden of cardiovascular disease, according to a new systematic review and meta-analysis in the British Journal of Dermatology. Study authors include